Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Type I Diabetes II: Pathophysiology

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...

Type I Diabetes I: Introduction

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Type II Diabetes I: Introduction

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Beta cell reactivity defines disease-relevant pancreatic CD8 T cells in type 1 diabetes.

bioRxiv : the preprint server for biology·2026

Same author

Submicron-sized ultrasound contrast agents as therapeutic peptide delivery vehicles in type 1 diabetes.

Theranostics·2026

Same author

Differences in Clinical Manifestations and Islet Autoantibodies by Age in Adult-Onset Type 1 Diabetes.

Diabetes care·2026

Same author

Teplizumab treatment for stage 2 type 1 diabetes: a real-world evaluation of metabolic and immunological outcomes.

Diabetologia·2026

Same author

Identifying Insulin Autoantibodies With Differential Risk in Type 1 Diabetes With a Novel Bridging ELISA.

Diabetes·2026

Same author

Quantitative V gene-targeted T cell receptor sequencing as a biomarker in type 1 diabetes.

JCI insight·2025

Search research articles

Related Experiment Video

Updated: May 30, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Immune intervention in type 1 diabetes.

Aaron W Michels¹, George S Eisenbarth

¹Barbara Davis Center for Childhood Diabetes, University of Colorado Denver, Aurora, CO 80045, USA.

Seminars in Immunology

|August 20, 2011

Summary

Type 1 diabetes (T1D) is an autoimmune disease destroying insulin-producing cells, with no cure. Research is exploring immunotherapies to prevent or slow beta cell destruction in T1D.

Area of Science:

Immunology
Endocrinology
Autoimmune Diseases

Background:

Type 1 diabetes (T1D) is a chronic autoimmune condition characterized by the immune-mediated destruction of insulin-producing beta cells.
Current T1D management involves lifelong insulin therapy, as no definitive cure exists.
The development of T1D involves complex immune dysregulation targeting pancreatic beta cells.

Purpose of the Study:

To review current immune intervention strategies for preventing and ameliorating human Type 1 diabetes.
To highlight ongoing research in immunotherapy for T1D, focusing on early-stage disease and at-risk individuals.
To explore novel therapeutic approaches including immune suppressive, antigen-specific, and environmental interventions.

Main Methods:

Review of existing literature on T1D immunotherapies.

More Related Videos

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Related Experiment Videos

Last Updated: May 30, 2026

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice

Published on: November 18, 2022

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes

Published on: August 20, 2007

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model

Published on: August 16, 2019

Analysis of data from research networks like TrialNet and the Immune Tolerance Network.

Focus on clinical trials evaluating immune-modulating agents.

Main Results:

Immunotherapies are under evaluation for their potential to halt or reverse beta cell destruction in T1D.
Research networks are crucial for advancing the clinical evaluation of these novel T1D treatments.
Several immune intervention strategies show promise in preclinical and early clinical studies.

Conclusions:

Immune intervention offers a promising avenue for preventing T1D onset or preserving beta cell function in established disease.
Targeting the autoimmune process in T1D could lead to more effective long-term management strategies.
Further research into immune suppressive, antigen-specific, and environmental therapies is essential for T1D prevention and treatment.